Is HYPOAESTHESIA a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed HYPOAESTHESIA.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 35 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported HYPOAESTHESIA to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and HYPOAESTHESIA. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause HYPOAESTHESIA, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes HYPOAESTHESIA. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if HYPOAESTHESIA ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing HYPOAESTHESIA: 35
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where HYPOAESTHESIA is a reported side effect: 1.0514%

FDA reports of any drug causing HYPOAESTHESIA : 45606
Average percentage for all medicated patients where HYPOAESTHESIA is reported as a complication: 0.2858%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
ANGINA PECTORIS ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with HYPOAESTHESIA:

TYSABRI (3765 patients)
ASPIRIN (3586 patients)
VIOXX (3554 patients)
FOSAMAX (3263 patients)
AVONEX (3214 patients)
ZOMETA (2712 patients)
HUMIRA (2398 patients)
LIPITOR (2231 patients)
LYRICA (2096 patients)
NEURONTIN (2056 patients)
ENBREL (2045 patients)
HEPARIN SODIUM INJECTION (1701 patients)
PREDNISONE (1634 patients)
SYNTHROID (1590 patients)
AREDIA (1574 patients)
LISINOPRIL (1519 patients)
XANAX (1507 patients)
NEXIUM (1491 patients)
REMICADE (1439 patients)
AMBIEN (1387 patients)
LASIX (1368 patients)
LEVAQUIN (1341 patients)
METHOTREXATE (1320 patients)
FORTEO (1306 patients)
COUMADIN (1306 patients)
SEROQUEL (1296 patients)
CELEBREX (1291 patients)
OXYCONTIN (1285 patients)
REBIF (1284 patients)
ZOLOFT (1236 patients)
GABAPENTIN (1158 patients)
ATENOLOL (1137 patients)
VICODIN (1112 patients)
HYDROCHLOROTHIAZIDE (1099 patients)
PRILOSEC (1098 patients)
PAXIL (1090 patients)
NORVASC (1052 patients)
CYMBALTA (1044 patients)
FOLIC ACID (1042 patients)
IBUPROFEN (1041 patients)
PLAVIX (1027 patients)
MAGNEVIST (1024 patients)
PROTONIX (1012 patients)
OMEPRAZOLE (1003 patients)
SIMVASTATIN (1002 patients)
VITAMIN D (999 patients)
PERCOCET (960 patients)
ALBUTEROL (955 patients)
TOPROL-XL (951 patients)
ZOCOR (929 patients)
DEXAMETHASONE (907 patients)
CRESTOR (902 patients)
ATIVAN (884 patients)
FUROSEMIDE (875 patients)
LORAZEPAM (874 patients)
PREVACID (868 patients)
LEXAPRO (854 patients)
ACETAMINOPHEN (848 patients)
DECADRON (823 patients)
OXYCODONE HCL (762 patients)
BETASERON (758 patients)
AVELOX (750 patients)
CALCIUM (734 patients)
DIOVAN (729 patients)
POTASSIUM CHLORIDE (706 patients)
ZOFRAN (705 patients)
YAZ (698 patients)
CLONAZEPAM (686 patients)
FLEXERIL (682 patients)
CHANTIX (678 patients)
DURAGESIC-100 (677 patients)
EFFEXOR (676 patients)
LEVOTHYROXINE SODIUM (675 patients)
ADVAIR DISKUS 100/50 (668 patients)
PREMARIN (667 patients)
ALPRAZOLAM (664 patients)
KLONOPIN (650 patients)
PROZAC (650 patients)
AMOXICILLIN (632 patients)
YASMIN (627 patients)
CELEXA (625 patients)
VALIUM (624 patients)
SINGULAIR (623 patients)
METFORMIN HCL (618 patients)
LORTAB (618 patients)
MORPHINE (609 patients)
ARIMIDEX (609 patients)
REVLIMID (601 patients)
TOPAMAX (601 patients)
THALIDOMIDE (593 patients)
DIGOXIN (590 patients)
VELCADE (590 patients)
WELLBUTRIN (588 patients)
BACLOFEN (587 patients)
PREDNISONE TAB (583 patients)
ALLOPURINOL (572 patients)
METOPROLOL TARTRATE (565 patients)
COMPAZINE (559 patients)
OMNISCAN (558 patients)
MULTI-VITAMINS (549 patients)
ZANTAC (547 patients)
WARFARIN SODIUM (540 patients)
LANTUS (539 patients)
TAXOTERE (534 patients)
ALLEGRA (531 patients)
GILENYA (518 patients)
DIAZEPAM (514 patients)
SANDOSTATIN LAR (513 patients)
BENADRYL (505 patients)
CIPROFLOXACIN (504 patients)
ARANESP (504 patients)
AMITRIPTYLINE HCL (499 patients)
PREDNISOLONE (497 patients)
MULTI-VITAMIN (495 patients)
FENTANYL (488 patients)
VITAMIN B-12 (482 patients)
ELAVIL (481 patients)
ZYRTEC (479 patients)
AVANDIA (475 patients)
NAPROXEN (474 patients)
ZYPREXA (474 patients)
VITAMIN E (463 patients)
XELODA (460 patients)
CLINDAMYCIN (459 patients)
DILAUDID (459 patients)
ULTRAM (459 patients)
INSULIN (455 patients)
TRAMADOL HCL (452 patients)
CIPRO (452 patients)
COREG (452 patients)
TRAZODONE HCL (446 patients)
SOMA (445 patients)
EPOGEN (444 patients)
CHEMOTHERAPEUTICS NOS (443 patients)
REGLAN (438 patients)
CLONIDINE (437 patients)
ASCORBIC ACID (435 patients)
TAMOXIFEN CITRATE (429 patients)
NITROGLYCERIN (429 patients)
FISH OIL (429 patients)
GLUCOPHAGE (415 patients)
CEPHALEXIN (412 patients)
MORPHINE SULFATE (411 patients)
MIRENA (410 patients)
EFFEXOR XR (409 patients)
BYETTA (404 patients)
SPIRIVA (402 patients)
HYDROCODONE BITARTRATE (399 patients)
CALCIUM CARBONATE (399 patients)
ZITHROMAX (399 patients)
TYLENOL (396 patients)
GLEEVEC (396 patients)
TAXOL (395 patients)
LOVENOX (394 patients)
AMLODIPINE (392 patients)
COLACE (390 patients)
FEMARA (381 patients)
TYLENOL (CAPLET) (381 patients)
ALENDRONATE SODIUM (377 patients)
ACTONEL (377 patients)
BEXTRA (373 patients)
MOTRIN (372 patients)
FLONASE (371 patients)
CYTOXAN (371 patients)
RADIATION THERAPY (370 patients)
COZAAR (367 patients)
ZETIA (365 patients)
RANITIDINE (360 patients)
FLUCONAZOLE (358 patients)
HYDROCODONE (358 patients)
VALTREX (357 patients)
PEPCID (354 patients)
EXTAVIA (353 patients)
METOPROLOL (351 patients)
ACTOS (346 patients)
CHLORHEXIDINE GLUCONATE (345 patients)
DOXYCYCLINE (344 patients)
HUMALOG (344 patients)
ACYCLOVIR (342 patients)
CITALOPRAM HYDROBROMIDE (335 patients)
KEFLEX (333 patients)
IRON (331 patients)
FLUOROURACIL (331 patients)
AUGMENTIN '125' (328 patients)
FLOMAX (327 patients)
CARBOPLATIN (327 patients)
LOPRESSOR (325 patients)
TEGRETOL (322 patients)
NIASPAN (321 patients)
PROCRIT /00909301/ (318 patients)
SKELAXIN (317 patients)
NUVARING (316 patients)
MIRALAX (314 patients)
BONIVA (314 patients)
ALTACE (313 patients)
LAMICTAL (310 patients)
RISPERDAL (310 patients)
RAMIPRIL (308 patients)
BACTRIM (308 patients)
PROMETHAZINE (308 patients)
FERROUS SULFATE TAB (307 patients)
AVASTIN (307 patients)
NASONEX (306 patients)
GLIPIZIDE (305 patients)
PAROXETINE HCL (303 patients)
DIFLUCAN (302 patients)
PLAQUENIL (301 patients)
NYSTATIN (301 patients)
VOLTAREN (298 patients)
PRAVACHOL (298 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about HYPOAESTHESIA and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.